아토피 피부염 치료제 시장 : 예측(2024-2029년)

The atopic dermatitis drugs market is estimated to grow at a CAGR of 8.92% during the forecast period.

One of the most prevalent inflammatory skin disorders is atopic dermatitis (AD). Although it might manifest differently in each person, eczematous and itchy skin lesions are the hallmarks of AD. Asthma, food allergies, and ocular conditions including conjunctivitis are just a few of the comorbidities associated with AD. Topical corticosteroids, calcineurin inhibitors, and injectable biologic drugs are frequently used to treat AD.

Growing prevalence of offspring atopic dermatitis

Patients with the atopic triad experience symptoms as a result of compromised skin, upper respiratory, and lower respiratory tract barrier. There is a greater than 50% likelihood that if one parent has atopic dermatitis, so will their child. Up to 80% of the kids will be impacted if both parents are sick. Genetic changes include loss-of-function mutations in the epidermal protein filaggrin (Filament aggregation protein), which is converted to a natural moisturizing factor. Up to 30% of those with atopic dermatitis have filaggrin mutations, which can also put them at risk for allergic rhinitis, ichthyosis vulgaris, and keratosis pilaris.

Rising incidences of atopic dermatitis

According to the National Library of Medicine, in wealthy nations, 2% to 10% of adults and 10% to 30% of children are affected by atopic dermatitis which highly impacts the atopic dermatitis drugs industry. In recent decades, its incidence has climbed by two to three times. Greater latitudes have a greater prevalence of atopic dermatitis, which may be due to less sun exposure and less humidity. Based on the age of onset, atopic dermatitis is categorized into three subgroups, the most prevalent kind of atopic dermatitis, with around 60% of cases beginning before age 1, is early-onset atopic dermatitis (birth to two years old). 60% of cases are settled by the age of 12. Atopic dermatitis with a late start occurs when symptoms appear after puberty. Senile onset atopic dermatitis is an uncommon subtype that develops in adults beyond the age of 60.

Growth in the usage of medication applied to the skin

Various medications come in a range of strengths and can be applied as creams, gels, or ointments boosting the atopic dermatitis drugs industry. Calcineurin inhibitor-containing lotions or ointments may be an option for patients older than two. Examples include tacrolimus (Protopic) and pimecrolimus (Elidel). The patient must keep out of the direct sun while using these drugs. Additionally, the Food and Drug Administration is obligated to put a black box warning on certain products addressing the potential for lymphoma. This warning has been given because of a small number of cases of lymphoma among users of topical calcineurin inhibitors.

Introduction of new treatments

The severity of the illness, both currently and in the past, as well as comorbidities, have a significant role in AD care. The development of the eczema illness is significantly influenced by the epidermal barrier. Patient education, emollient treatment, and trigger avoidance are all part of the initial care. Emollients can be just as beneficial as topical corticosteroids (TCS) of low potency and have been shown to decrease the incidence of AD. In December 2022, the innovative, patient-tailored monoclonal antibody therapy rocatinlimab demonstrated excellent outcomes in patients with moderate to severe atopic dermatitis throughout the study and for up to 20 weeks after the treatment was terminated. This development is boosting the growth of the atopic dermatitis drug market.

In North America, it is projected that the atopic dermatitis drugs market will grow steadily.

The atopic dermatitis drug market in North America is anticipated to be fueled by the growing prevalence of atopic dermatitis and research initiatives in the region. For instance, a brand-new national skin research network called SkIN Canada (Skin Investigation Network of Canada) was introduced. Research priorities that are significant to patients, carers, and healthcare professionals are being established to influence the research landscape and guarantee its usefulness to patient care. By providing a coordinated multidisciplinary approach to patient management of AD, the integrated care pathways for atopic dermatitis (AD-ICPs) seek to close the gap between current AD treatment evidence-based guidelines and expert opinion based on everyday practice. Moreover, by combining interventions and elements from many guidelines, including quality assurance, and explaining care coordination, ICPs have the potential to improve guideline recommendations.

Atopic Dermatitis Clinical Trials

• In August 2023, Positive topline statistics from the LNK01001 phase II clinical study for adults with atopic dermatitis (AD) were released by Lynk Pharmaceuticals Co., Ltd. Preliminary data after 12 weeks of therapy revealed that patients in the low-dose and high-dose groups significantly improved their Eczema Area and Severity Index (EASI) ratings from baseline compared to the placebo group.
• In August 2023, the phase 3 clinical research for MH004 Cream, which targets mild to moderate atopic dermatitis, successfully enrolled its first patient, according to Minghui Pharmaceutical, Inc., a prominent clinical-stage biopharmaceutical business. This accomplishment represents a crucial turning point in the effort to provide patients suffering from this common skin ailment with new and cutting-edge therapeutic choices.

FDA Approvals for Atopic Dermatitis Drugs Drugs

• In June 2022, Dupixent® (dupilumab) was authorized by the U.S. Food and Drug Administration (FDA) for use in children with moderate-to-severe atopic dermatitis who are 6 months to 5 years old and whose condition is not well managed by topical prescription medications or when such therapies are not recommended.
• In January 2022, The U.S. Food and Drug Administration (FDA) has authorized CIBINQO® (abrocitinib), an oral, once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of adults with refractory, moderate-to-severe-atopic dermatitis (AD), according to Pfizer Inc.
• In January 2022, RINVOQ® (upadacitinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to prior therapy and is not well controlled with other pills or injections, including biologic medications, or when use of other pills or injections is not advised.

Market Key Developments

• In May 2023, according to the information from a new secondary analysis from Eli Lilly and Company's Phase 3 clinical development program patients receiving lebrikizumab who were evaluated at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body.
• In June 2021, Amgen and Kyowa Kirin Co., Ltd. reached a deal to work together to develop and market KHK4083, a potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody that Kyowa Kirin is currently developing for the treatment of atopic dermatitis with potential for use in other autoimmune diseases.

Segmentation:

By Drug

• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

By Route of Administration

• Topical
• Injectable
• Oral

By End-User

• Hospitals
• Clinics
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. ATOPIC DERMATITIS DRUGS MARKET, BY DRUG

• 5.1. Introduction
• 5.2. Corticosteroids
• 5.3. Calcineurin Inhibitors
• 5.4. PDE4 Inhibitors
• 5.5. Biologics
• 5.6. Others

6. ATOPIC DERMATITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 6.1. Introduction
• 6.2. Topical
• 6.3. Injectable
• 6.4. Oral

7. ATOPIC DERMATITIS DRUGS MARKET, BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Clinics
• 7.4. Others

8. ATOPIC DERMATITIS DRUGS MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Fierce Pharma
• 10.2. Pfizer
• 10.3. Optum
• 10.4. Mayo Clinic
• 10.5. Adbry
• 10.6. JW Pharmaceuticals
• 10.7. Acrcutis Biotherapeutics
• 10.8. Regeneron
• 10.9. Otsuka
• 10.10. Eli Lilly